Magnetic seizure therapy in an adolescent with refractory bipolar depression

A case report

Yoshihiro Noda, Zafiris J. Daskalakis, Jonathan Downar, Paul E Croarkin, Paul B. Fitzgerald, Daniel M. Blumberger

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Magnetic seizure therapy (MST) has shown efficacy in adult patients with treatment-resistant depression with limited impairment in memory. To date, the use of MST in adolescent depression has not been reported. Here we describe the first successful use of MST in the treatment of an adolescent patient with refractory bipolar depression. This patient received MST in an ongoing open-label study for treatment-resistant major depression. Treatments employed a twin-coil MST apparatus, with the center of each coil placed over the frontal cortex (ie, each coil centered over F3 and F4). MST was applied at 100 Hz and 100% machine output at progressively increasing train durations. Depressive symptoms were assessed using the 24-item Hamilton Depression Rating Scale and cognitive function was assessed with a comprehensive neuropsychological battery. This adolescent patient achieved full remission of clinical symptoms after an acute course of 18 MST treatments and had no apparent cognitive decline, other than some autobiographical memory impairment that may or may not be related to the MST treatment. This case report suggests that MST may be a safe and well tolerated intervention for adolescents with treatment-resistant bipolar depression. Pilot studies to further evaluate the effectiveness and safety of MST in adolescents warrant consideration.

Original languageEnglish (US)
Pages (from-to)2049-2055
Number of pages7
JournalNeuropsychiatric Disease and Treatment
Volume10
DOIs
StatePublished - Nov 3 2014

Fingerprint

Treatment-Resistant Depressive Disorder
Bipolar Disorder
Seizures
Therapeutics
Depression
Episodic Memory
Frontal Lobe

Keywords

  • Adolescent depression
  • Brain stimulation
  • Cognitive effects
  • Treatment-resistant depression

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

Magnetic seizure therapy in an adolescent with refractory bipolar depression : A case report. / Noda, Yoshihiro; Daskalakis, Zafiris J.; Downar, Jonathan; Croarkin, Paul E; Fitzgerald, Paul B.; Blumberger, Daniel M.

In: Neuropsychiatric Disease and Treatment, Vol. 10, 03.11.2014, p. 2049-2055.

Research output: Contribution to journalArticle

Noda, Yoshihiro ; Daskalakis, Zafiris J. ; Downar, Jonathan ; Croarkin, Paul E ; Fitzgerald, Paul B. ; Blumberger, Daniel M. / Magnetic seizure therapy in an adolescent with refractory bipolar depression : A case report. In: Neuropsychiatric Disease and Treatment. 2014 ; Vol. 10. pp. 2049-2055.
@article{3cb5ae6bbb6446dd936abdf226f2c347,
title = "Magnetic seizure therapy in an adolescent with refractory bipolar depression: A case report",
abstract = "Magnetic seizure therapy (MST) has shown efficacy in adult patients with treatment-resistant depression with limited impairment in memory. To date, the use of MST in adolescent depression has not been reported. Here we describe the first successful use of MST in the treatment of an adolescent patient with refractory bipolar depression. This patient received MST in an ongoing open-label study for treatment-resistant major depression. Treatments employed a twin-coil MST apparatus, with the center of each coil placed over the frontal cortex (ie, each coil centered over F3 and F4). MST was applied at 100 Hz and 100{\%} machine output at progressively increasing train durations. Depressive symptoms were assessed using the 24-item Hamilton Depression Rating Scale and cognitive function was assessed with a comprehensive neuropsychological battery. This adolescent patient achieved full remission of clinical symptoms after an acute course of 18 MST treatments and had no apparent cognitive decline, other than some autobiographical memory impairment that may or may not be related to the MST treatment. This case report suggests that MST may be a safe and well tolerated intervention for adolescents with treatment-resistant bipolar depression. Pilot studies to further evaluate the effectiveness and safety of MST in adolescents warrant consideration.",
keywords = "Adolescent depression, Brain stimulation, Cognitive effects, Treatment-resistant depression",
author = "Yoshihiro Noda and Daskalakis, {Zafiris J.} and Jonathan Downar and Croarkin, {Paul E} and Fitzgerald, {Paul B.} and Blumberger, {Daniel M.}",
year = "2014",
month = "11",
day = "3",
doi = "10.2147/NDT.S71056",
language = "English (US)",
volume = "10",
pages = "2049--2055",
journal = "Neuropsychiatric Disease and Treatment",
issn = "1176-6328",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Magnetic seizure therapy in an adolescent with refractory bipolar depression

T2 - A case report

AU - Noda, Yoshihiro

AU - Daskalakis, Zafiris J.

AU - Downar, Jonathan

AU - Croarkin, Paul E

AU - Fitzgerald, Paul B.

AU - Blumberger, Daniel M.

PY - 2014/11/3

Y1 - 2014/11/3

N2 - Magnetic seizure therapy (MST) has shown efficacy in adult patients with treatment-resistant depression with limited impairment in memory. To date, the use of MST in adolescent depression has not been reported. Here we describe the first successful use of MST in the treatment of an adolescent patient with refractory bipolar depression. This patient received MST in an ongoing open-label study for treatment-resistant major depression. Treatments employed a twin-coil MST apparatus, with the center of each coil placed over the frontal cortex (ie, each coil centered over F3 and F4). MST was applied at 100 Hz and 100% machine output at progressively increasing train durations. Depressive symptoms were assessed using the 24-item Hamilton Depression Rating Scale and cognitive function was assessed with a comprehensive neuropsychological battery. This adolescent patient achieved full remission of clinical symptoms after an acute course of 18 MST treatments and had no apparent cognitive decline, other than some autobiographical memory impairment that may or may not be related to the MST treatment. This case report suggests that MST may be a safe and well tolerated intervention for adolescents with treatment-resistant bipolar depression. Pilot studies to further evaluate the effectiveness and safety of MST in adolescents warrant consideration.

AB - Magnetic seizure therapy (MST) has shown efficacy in adult patients with treatment-resistant depression with limited impairment in memory. To date, the use of MST in adolescent depression has not been reported. Here we describe the first successful use of MST in the treatment of an adolescent patient with refractory bipolar depression. This patient received MST in an ongoing open-label study for treatment-resistant major depression. Treatments employed a twin-coil MST apparatus, with the center of each coil placed over the frontal cortex (ie, each coil centered over F3 and F4). MST was applied at 100 Hz and 100% machine output at progressively increasing train durations. Depressive symptoms were assessed using the 24-item Hamilton Depression Rating Scale and cognitive function was assessed with a comprehensive neuropsychological battery. This adolescent patient achieved full remission of clinical symptoms after an acute course of 18 MST treatments and had no apparent cognitive decline, other than some autobiographical memory impairment that may or may not be related to the MST treatment. This case report suggests that MST may be a safe and well tolerated intervention for adolescents with treatment-resistant bipolar depression. Pilot studies to further evaluate the effectiveness and safety of MST in adolescents warrant consideration.

KW - Adolescent depression

KW - Brain stimulation

KW - Cognitive effects

KW - Treatment-resistant depression

UR - http://www.scopus.com/inward/record.url?scp=84908458898&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908458898&partnerID=8YFLogxK

U2 - 10.2147/NDT.S71056

DO - 10.2147/NDT.S71056

M3 - Article

VL - 10

SP - 2049

EP - 2055

JO - Neuropsychiatric Disease and Treatment

JF - Neuropsychiatric Disease and Treatment

SN - 1176-6328

ER -